The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Temperature-responsive silk-elastinlike protein polymer enhancement of intravesical drug delivery of a therapeutic glycosaminoglycan for treatment of interstitial cystitis/painful bladder syndrome
Abstract
Interstitial cystitis (IC), also known as painful bladder syndrome, is a debilitating chronic condition with many patients failing to respond to current treatment options. Rapid clearance, mucosal coating, and tight epithelium create strong natural barriers that reduce the effectiveness of many pharmacological interventions in the bladder. Intravesical drug delivery (IDD) is the administration of therapeutic compounds or devices to the urinary bladder via a urethral catheter. Previous work in improving IDD for IC has focused on the sustained delivery of analgesics within the bladder and other small molecule drugs which do not address underlying inflammation and bladder damage. Therapeutic glycosaminoglycans (GAG) function by restoring the mucosal barrier within the bladder, promoting healing responses, and preventing irritating solutes from reaching the bladder wall. There is an unmet medical need for a therapy that provides both acute relief of symptoms while alleviating underlying physiological sources of inflammation and promoting healing within the urothelium. Semi-synthetic glycosaminoglycan ethers (SAGE) are an emerging class of therapeutic GAG with intrinsic anti-inflammatory and analgesic properties. To reduce SAGE clearance and enhance its accumulation in the bladder, we developed a silk-elastinlike protein polymer (SELP) based system to enhance SAGE IDD. We evaluated in vitro release kinetics, rheological properties, impact on bladder function, pain response, and bladder inflammation and compared their effectiveness to other temperature-responsive polymers including Poloxamer 407 and poly(lactic-co-glycolic acid)-poly(ethylene glycol). SAGE delivered via SELP-enhanced intravesical delivery substantially improved SAGE accumulation in the urothelium, provided a sustained analgesic effect 24 hrs. after administration, and reduced inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SELP hydrogels have been used for controlled release of therapeutics in the local environment [43,44,45,46,47].”
In the citing paper
“Among different analogs, the specific sequence of silk and elastin units enables SELP-815K to act as a thermoresponsive polymer that is liquid at room temperature and forms a hydrogel at body temperature [41,43,44,45,46,48].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome: AUA Guideline Amendment
Hanno, P. M., Erickson, D., Moldwin, R., & Faraday, M. M. (2015) · Journal of Urology · doi:10.1016/j.juro.2015.01.086 · Cited by 692
Chromek, M., Slamová, Z., Bergman, P., Kovács, L., Podracká, L., Ehrén, I., Hökfelt, T., Gudmundsson, G. H., Gallo, R. L., Agerberth, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1407 · Cited by 652
Research works printed but not linked: 58
- Elbadawi, 1997, Interstitial cystitis: a critique of current concepts with a new proposal for pathologic diagnosis and pathogenesis, Urology, 49, 14, 10.1016/S0090-4295(99)80329-X · DOI · Paper page
- Lee, 2013, Prevention of anti-microbial peptide LL-37-induced apoptosis and ATP release in the urinary bladder by a modified glycosaminoglycan, PLoS One, 8
- Nickel, 2012, Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device, Sci. Transl. Med., 4, 143ra100, 10.1126/scitranslmed.3003804 · DOI
- Parsons, 1994, Treatment of interstitial cystitis with intravesical heparin, Br. J. Urol., 73, 504, 10.1111/j.1464-410X.1994.tb07634.x · doi:10.1111/j.1464-410x.1994.tb07634.x
- Welk, 2008, Dyspareunia response in patients with interstitial cystitis treated with intravesical lidocaine, bicarbonate, and heparin, Urology, 71, 67, 10.1016/j.urology.2007.09.067 · DOI
- Nickel, 2009, Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome, BJU Int., 103, 910, 10.1111/j.1464-410X.2008.08162.x · DOI
- Parsons, 2012, Alkalinized lidocaine and heparin provide immediate relief of pain and urgency in patients with interstitial cystitis, J. Sex. Med., 9, 207, 10.1111/j.1743-6109.2011.02542.x · doi:10.1111/j.1743-6109.2011.02542.x
- Lamarre, 2015, Treatment of painful bladder syndrome/interstitial cystitis with botulinum toxin A: why isn't it effective in all patients?, Transl. Androl. Urol., 4, 543
- Krhut, 2016, Intravesical instillation of onabotulinum toxin A embedded in inert hydrogel in the treatment of idiopathic overactive bladder: a double-blind randomized pilot study, Scand. J. Urol., 50, 200, 10.3109/21681805.2015.1121406 · doi:10.3109/21681805.2015.1121406
- Chuang, 2017, A prospective, multicenter, double-blind, randomized trial of bladder instillation of liposome formulation OnabotulinumtoxinA for interstitial cystitis/bladder pain syndrome, J. Urol., 198, 376, 10.1016/j.juro.2017.02.021 · DOI
- Pulsipher, 2017, Prevention of sinonasal inflammation by a synthetic glycosaminoglycan, Int. Forum Allergy Rhinol., 7, 177, 10.1002/alr.21865 · DOI
- Kaufman, 2010, State of the art in intravesical therapy for lower urinary tract symptoms, Rev. Urol., 12, e181
- GuhaSarkar, 2010, Intravesical drug delivery: challenges, current status, opportunities and novel strategies, J. Control. Release, 148, 147, 10.1016/j.jconrel.2010.08.031 · DOI · Paper page
- Zacchè, 2015, Novel targeted bladder drug-delivery systems: a review, Res. Rep. Urol., 7, 169
- Karimi, 2016, Temperature-responsive smart nanocarriers for delivery of therapeutic agents: applications and recent advances, ACS Appl. Mater. Interfaces, 8, 21107, 10.1021/acsami.6b00371 · DOI · Paper page
- Price, 2014, Controlled release from recombinant polymers, J. Control. Release, 190, 304, 10.1016/j.jconrel.2014.06.016 · DOI
- Ciofani, 2014, The potential of recombinant human elastin-like polypeptides for drug delivery, Expert Opin. Drug Deliv., 11, 1507, 10.1517/17425247.2014.926885 · doi:10.1517/17425247.2014.926885
- Megeed, 2002, Genetically engineered silk-elastinlike protein polymers for controlled drug delivery, Adv. Drug Deliv. Rev., 54, 1075, 10.1016/S0169-409X(02)00063-7 · DOI · Paper page
- Dandu, 2009, Silk–elastinlike protein polymer hydrogels: influence of monomer sequence on physicochemical properties, Polymer, 50, 366, 10.1016/j.polymer.2008.11.047 · DOI · Paper page
- Price, 2015, In vivo evaluation of matrix metalloproteinase responsive silk–elastinlike protein polymers for cancer gene therapy, J. Control. Release, 213, 96, 10.1016/j.jconrel.2015.06.022 · DOI
- Poursaid, 2016, Silk-elastinlike protein polymer liquid chemoembolic for localized release of doxorubicin and sorafenib, Mol. Pharm., 13, 2736, 10.1021/acs.molpharmaceut.6b00325 · DOI · Paper page
- Poursaid, 2015, In situ gelling silk-elastinlike protein polymer for transarterial chemoembolization, Biomaterials, 57, 142, 10.1016/j.biomaterials.2015.04.015 · DOI · Paper page
- Price, 2014, Effect of shear on physicochemical properties of matrix metalloproteinase responsive silk-elastinlike hydrogels, J. Control. Release, 195, 92, 10.1016/j.jconrel.2014.07.044 · DOI
- Gustafson, 2013, Synthesis and characterization of a matrix-metalloproteinase responsive silk–elastinlike protein polymer, Biomacromolecules, 14, 618, 10.1021/bm3013692 · DOI
- Haider, 2005, Molecular engineering of silk-elastinlike polymers for matrix-mediated gene delivery: biosynthesis and characterization, Mol. Pharm., 2, 139, 10.1021/mp049906s · DOI
- Jensen, 2017, Silk-elastinlike protein polymers enhance the efficacy of a therapeutic glycosaminoglycan for prophylactic treatment of radiation-induced proctitis, J. Control. Release, 263, 46, 10.1016/j.jconrel.2017.02.025 · DOI · Paper page
- Price, 2012, Comparison of silk-elastinlike protein polymer hydrogel and poloxamer in matrix-mediated gene delivery, Int. J. Pharm., 427, 97, 10.1016/j.ijpharm.2011.09.037 · DOI
- Dandu, 2008, Characterization of structurally related adenovirus-laden silk-elastinlike hydrogels, J. Bioact. Compat Polym., 23, 5, 10.1177/0883911507085278 · DOI
- Gao, 2010, PLGA-PEG-PLGA hydrogel for ocular drug delivery of dexamethasone acetate, Drug Dev. Ind. Pharm., 36, 1131, 10.3109/03639041003680826 · DOI
- Yu, 2008, Injectable block copolymer hydrogels for sustained release of a PEGylated drug, Int. J. Pharm., 348, 95, 10.1016/j.ijpharm.2007.07.026 · DOI · Paper page
- Fakhari, 2017, Thermogelling properties of purified poloxamer 407, Heliyon, 3, 10.1016/j.heliyon.2017.e00390 · DOI · Paper page
- Jia, 2017, Bladder pain in an LL-37 interstitial cystitis and painful bladder syndrome model, Am. J. Clin. Exp. Urol., 5, 10
- Oottamasathien, 2013, Physiological relevance of LL-37 induced bladder inflammation and mast cells, J. Urol., 190, 1596, 10.1016/j.juro.2013.01.002 · DOI
- Oottamasathien, 2011, A murine model of inflammatory bladder disease: cathelicidin peptide induced bladder inflammation and treatment with sulfated polysaccharides, J. Urol., 186, 1684, 10.1016/j.juro.2011.03.099 · DOI
- Rudick, 2009, Pharmacologic attenuation of pelvic pain in a murine model of interstitial cystitis, BMC Urol., 9, 1, 10.1186/1471-2490-9-16 · DOI
- Cappelleri, 2009, Pain responder analysis: use of area under the curve to enhance interpretation of clinical trial results, Pain Pract., 9, 348, 10.1111/j.1533-2500.2009.00293.x · DOI
- Yu, 2014, Spontaneous voiding by mice reveals strain-specific lower urinary tract function to be a quantitative genetic trait, Am. J. Physiol. Physiol., 306, F1296, 10.1152/ajprenal.00074.2014 · DOI
- Erickson, 2006, Molecular Size Affects Urine Excretion of Pentosan Polysulfate, 175, 1143
- Faaij, 1999, The oral bioavailability of pentosan polysulphate sodium in healthy volunteers, Eur. J. Clin. Pharmacol., 54, 929, 10.1007/s002280050577 · doi:10.1007/s002280050577
- Davis, 2008, Safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: a randomized double-blind clinical trial, J. Urol., 179, 177, 10.1016/j.juro.2007.08.170 · doi:10.1016/j.juro.2007.08.170
- Cox, 2016, CUA guideline: diagnosis and treatment of interstitial cystitis/bladder pain syndrome, Can. Urol. Assoc. J., 10, E136, 10.5489/cuaj.3786 · DOI
- Zhang, 2011, Novel sulfated polysaccharides disrupt cathelicidins, inhibit RAGE and reduce cutaneous inflammation in a mouse model of rosacea, PLoS One, 6
- Savage, 2016, A modified glycosaminoglycan, GM-0111, inhibits molecular signaling involved in periodontitis, PLoS One, 11, 10.1371/journal.pone.0157310 · DOI
- Martin Jensen, 2018, IL-33 mast cell axis is central in LL-37 induced bladder inflammation and pain in a murine interstitial cystitis model, Cytokine, 110, 420, 10.1016/j.cyto.2018.05.012 · DOI
- Lin, 2016, Floating hydrogel with self-generating micro-bubbles for intravesical instillation, Materials, 9, E1005, 10.3390/ma9121005 · doi:10.3390/ma9121005
- Donin, 2017, Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: safety and feasibility, Urol. Oncol. Semin. Orig. Investig., 35, 272
- Lin, 2017, Thermo reversible hydrogel based delivery of mitomycin C for treatment of upper tract urothelial carcinoma (UTUC), J. Clin. Oncol., 35, 10.1200/JCO.2017.35.15_suppl.e16089 · doi:10.1200/jco.2017.35.15_suppl.e16089
- Chen, 2017, Evaluating the voiding spot assay in mice: a simple method with complex environmental interactions, Am. J. Physiol. Physiol., 313, F1274, 10.1152/ajprenal.00318.2017 · DOI
- Jacobsen, 2012, Postsurgical food and water consumption, fecal corticosterone metabolites, and behavior assessment as noninvasive measures of pain in vasectomized BALB/c mice, J. Am. Assoc. Lab. Anim. Sci., 51, 69
- Janicki, 2015, Intravesical liposome drug delivery and IC/BPS, Transl, Androl. Urol., 4, 572
- Chuang, 2009, Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome, J. Urol., 182, 1393, 10.1016/j.juro.2009.06.024 · doi:10.1016/j.juro.2009.06.024
- Tyagi, 2017, Intravesical liposome therapy for interstitial cystitis, Int. J. Urol., 24, 262, 10.1111/iju.13317 · DOI
- Janicki, 2016, Potential effect of liposomes and liposome-encapsulated botulinum toxin and tacrolimus in the treatment of bladder dysfunction, Toxins, 8, 81, 10.3390/toxins8030081 · doi:10.3390/toxins8030081
- Chancellor, 2001, Future trends in the treatment of urinary incontinence, Rev. Urol., 3, S27
- Killinger, 2013, Pain in interstitial cystitis/bladder pain syndrome: do characteristics differ in ulcerative and non-ulcerative subtypes?, Int. Urogynecol. J., 24, 1295, 10.1007/s00192-012-2003-9 · doi:10.1007/s00192-012-2003-9
- Laird, 2001, A new model of visceral pain and referred hyperalgesia in the mouse, Pain, 92, 335, 10.1016/S0304-3959(01)00275-5 · DOI · Paper page
- Birder, 2018, Animal modelling of interstitial cystitis/bladder pain syndrome, Int. Neurourol. J., 22, S3, 10.5213/inj.1835062.531 · DOI
- Tyagi, 2014, Pathophysiology and animal modeling of underactive bladder, Int. Urol. Nephrol., 46, 11, 10.1007/s11255-014-0808-9 · DOI
Cited by
Recent trends in protein and peptide-based biomaterials for advanced drug delivery
Varanko, A., Saha, S., & Chilkoti, A. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.08.008 · Cited by 369
Yathavan, B., Chhibber, T., Steinhauff, D., Pulsipher, A., Alt, J. A., Ghandehari, H., & Jafari, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102426 · Cited by 20
Self-citation
Metadata
- Authors
- Jensen, M. M., Jia, W., Schults, A. J., Isaacson, K. J., Steinhauff, D., Green, B., Zachary, B., Cappello, J., Ghandehari, H., & Oottamasathien, S.
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 217
- Pages
- 119293
- ISSN
- 0142-9612
- Cited by
- 41
- References
- 2
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (am, 274 d)
- Funders
- National Science Foundation
- National Institutes of Health
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Temperature-responsive silk-elastinlike protein polymer enhancement of intravesical drug delivery of a therapeutic glycosaminoglycan for treatment of interstitial cystitis/painful bladder syndrome. https://app.cochat.ai/papers/10.1016/j.biomaterials.2019.119293
- The paper
- Jensen, M. M., Jia, W., Schults, A. J., Isaacson, K. J., Steinhauff, D., Green, B., Zachary, B., Cappello, J., Ghandehari, H., & Oottamasathien, S. (2019). Temperature-responsive silk-elastinlike protein polymer enhancement of intravesical drug delivery of a therapeutic glycosaminoglycan for treatment of interstitial cystitis/painful bladder syndrome. Biomaterials. https://doi.org/10.1016/j.biomaterials.2019.119293
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.